Servier and Neurochlore have recently announced that, following a lack of efficacy in two Phase III trials of bumetanide for autism spectrum disorder (ASD) in adolescents, they would be terminating these trials early. These results are particularly disappointing given the promise bumetanide had shown in an earlier Phase IIb trial, and because there is a large unmet need for treatments for the core symptoms of ASD, says GlobalData. The leadng data and analytics company notes that currently, the only FDA-approved drugs for autism are the atypical antipsychotics, which aim to treat the associated symptom of irritability.
The large unmet need …
Related posts:
It’s raining tech unicorns in India with increasing digital adoption, says GlobalData
Netherlands on track to phase out coal power by 2030, says GlobalData
New low-cost start-up Bonza Airlines set to fill void in Australia’s domestic routes, says GlobalDat...
Reduced risk of CV morbidity and mortality demonstrated in FIGARO-DKD study
